TITLE

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

AUTHOR(S)
Mcgarvey, Lorcan P.; John, Matthias; Anderson, Julie A.; Zvarich, Michael; Wise, Robert A.
PUB. DATE
May 2007
SOURCE
Thorax;May2007, Vol. 62 Issue 5, p411
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). The primary outcome is all-cause mortality. Cause-specific mortality and deaths related to COPD are additional outcome measures, but systematic methods for ascertainment of these outcomes have not previously been described. Methods: A Clinical Endpoint Committee (CEC) was tasked with categorising the cause of death and the relationship of deaths to COPD in a systematic, unbiased and independent manner. The key elements of the operation of the committee were the use of predefined principles of operation and definitions of cause of death and COPD-relatedness; the independent review of cases by all members with development of a consensus opinion; and a substantial infrastructure to collect medical information. Results: 911 deaths were reviewed and consensus was reached in all. Cause-specific mortality was: cardiovascular 27%, respiratory 35%, cancer 21%, other 10% and unknown 8%. 40% of deaths were definitely or probably related to COPD. Adjudications were identical in 83% of blindly re-adjudicated cases (κ=0.80). COPD-relatedness was reproduced 84% of the time (κ=0.73). The CEC adjudication was equivalent to the primary cause of death recorded by the site investigator in 52% of cases. Conclusion: A CEC can provide standardised, reliable and informative adjudication of COPD mortality that provides information which frequently differs from data collected from assessment by site investigators.
ACCESSION #
25142217

 

Related Articles

  • Parsing the death toll of COPD. Kuritzky, Louis // Clinical Cardiology Alert;Oct2010 Pharmacology, p19 

    The article discusses research study on mortality rate of chronic obstructive pulmonary disease (COPD), which references a study by B. Zvezdin et el, published in a 2009 issue of "Chest."

  • Parsing the death toll of COPD.  // Clinical Oncology Alert;Oct2010 Supplement, p19 

    No abstract available.

  • Theravance, GSK Testing COPD Combo Treatment.  // Bioworld Week;11/2/2009, Vol. 17 Issue 44, p4 

    The article reports on the start of the first in a series of Phase III studies of next-generation combination treatment for chronic obstructive pulmonary disorder (COPD) of Theravance Inc. and GlaxoSmithKline PLC. The studies will include over 6,000 patients with COPD and will evaluate the rate...

  • Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial. Rennard, Stephen I.; Tashkin, Donald P.; McElhattan, Jennifer; Goldman, Mitchell; Ramachandran, Sulabha; Martin, Ubaldo J.; Silkoff, Philip E. // Drugs;2009, Vol. 69 Issue 5, p549 

    Background: Combination therapy with a long-acting bronchodilator and an inhaled corticosteroid (ICS) is recommended in patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. The efficacy and tolerability of the combination of budesonide/formoterol have been...

  • LUNG ALERT: Combination treatment may help patients with COPD, but does not improve mortality. Ampikaipakan, Sundari // Thorax;Jul2007, Vol. 62 Issue 7, p587 

    The article reports on the research findings on combination treatment of patients with chronic obstructive pulmonary disease (COPD). It is stated that although the salmeterol-fluticasone combination failed to demonstrate an improvement in mortality according to the predefined statistical...

  • Combination therapy for airflow limitation in COPD. Ghanei, Mostafa; Nezhad, Leila Hoseini; Harandi, Ali Amini; Alaeddini, Farshid; Shohrati, Majid; Aslani, Jafar // DARU;2012, Vol. 20, p1 

    Abstract: Background and the purpose of the study Existing evidence confirms that no pharmacologic agent ameliorates the decline in the lung function or changes the prognosis of chronic obstructive pulmonary disease (COPD). We tried a critical combination therapy for management of COPD. Methods:...

  • CLINICAL TRIAL DIGEST.  // Pulmonary Reviews;Mar2008, Vol. 13 Issue 3, p11 

    The article offers information on findings from clinical trials published in several journals. A study of asthmatic children found no beneficial effects with the addition of a nebulized recombinant human deoxyribonuclease (rhDNase) to the standard treatment. A study found that fluticasone plus...

  • Practice nurses play key role in unique clinical trial.  // Practice Nurse;12/19/2014, Vol. 44 Issue 12, p10 

    The article discusses the Salford Lung Study led by research nurse Anita Kania on a medicine prior to approval conducted among more than 60 nurses from 55 general practices. The study involves a range of people who are more representative of the population in which the drug would be prescribed...

  • Registrar: MRCGP Exam update - Asthma management. Newson, Louise // GP: General Practitioner;5/13/2005, p90 

    This article focuses on clinical features of asthma and on associated latest therapeutic developments. Asthma, reportedly, is a multi-faceted disease process with intermittent smooth muscle contraction causing airflow obstruction and underlying endobronchial inflammation. The dose-response curve...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics